Merck & Co., Inc. (NYSE:MRK) Stock Gets Price Target Bump from JPMorgan Chase & Co.

Merck & Co., Inc. (NYSE:MRK) had its target price raised by JPMorgan Chase & Co. from $165.00 to $175.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 16.86% from the company’s previous close.

A number of other research analysts have also recently commented on MRK. Wells Fargo & Company increased their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. UBS Group lifted their price target on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Leerink Partners upped their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. Scotiabank boosted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a report on Tuesday, September 29th. Finally, Guggenheim increased their target price on shares of Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a research note on Friday. Seventeen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $153.36.

Merck & Co., Inc. Trading Up 2.3%

Merck & Co., Inc. stock traded up $3.42 during trading hours on Friday, hitting $149.75. The company had a trading volume of 12,341,136 shares, compared to its average volume of 10,677,021. The firm has a market cap of $369.46 billion, a P/E ratio of 119.80, a P/E/G ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a 50-day moving average price of $146.89 and a two-hundred day moving average price of $126.49.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm earned $2.58 earnings per share. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 2.64 earnings per share for the current year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Richard Deluca sold 20,784 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This trade represents a 13.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares of the company’s stock, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company’s stock.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds have recently made changes to their positions in MRK. MFG Investments LLC acquired a new position in shares of Merck & Co., Inc. in the third quarter valued at $364,000. Provenance Wealth Advisors LLC increased its stake in Merck & Co., Inc. by 997.3% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 16,811 shares of the company’s stock valued at $2,443,000 after buying an additional 15,279 shares during the last quarter. Hughes Financial Services LLC raised its position in shares of Merck & Co., Inc. by 10.7% during the 3rd quarter. Hughes Financial Services LLC now owns 1,286 shares of the company’s stock valued at $188,000 after buying an additional 124 shares in the last quarter. Integras Partners LLC purchased a new stake in Merck & Co., Inc. in the 3rd quarter worth approximately $223,000. Finally, Lyell Wealth Management LP raised its stake in shares of Merck & Co., Inc. by 4.4% in the third quarter. Lyell Wealth Management LP now owns 11,294 shares of the company’s stock worth $1,641,000 after purchasing an additional 478 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.